RHS
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
RHS Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual capital growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
0
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
RHS Limited
π Performance
Price History
-100.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in RHS
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in RHS
N/A
RHS investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in RHS also invest in...
Want more shares? Try these...
Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. The firm specializes in the development and delivery of non-invasive medical imaging software and services. The firm is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The firm's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The firm also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.
π Share price